EKF Diagnostics, worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays, has announced the launch of a new division to focus on molecular and companion diagnostics.
EKF Molecular Diagnostics will develop technologies for cancer gene detection through its acquisition of UK-based 360 Genomics.